1. Market Research
  2. > Life Sciences
16 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Global Lupus Nephritis Market Report - 2026

  • $ 3849
  • July 2018
  • 99 pages

The most severe form of LN, called diffuse proliferative nephritis, can cause scars to form in the kidneys. [...] People who have LN are at a high risk for cancer, primarily B-cell lymphoma, a type of cancer that begins in the cells of the immune system.

  • World
  • Musculoskeletal Disorder
  • Genitourinary System Disease
  • Industry analysis
  • Drug Approval
  • Life Expectancy

Benign Prostatic Hyperplasia - Pipeline Review, H1 2020

  • $ 2000
  • May 2020
  • 121 pages

The company's pipeline products include BR1006, BR1007, BR1008 for treating hypertension; BR2002, a drug used to treat lymphoma; and BR8003, a vaccine designed for the treatment of Hepatitis A. It also develops Kanarb, a drug used to treat hypertension; and Gelfos, an antacid for the treatment of hypergastric acidity, gastritis and gastric fullness.

  • World
  • Pharmaceutical
  • Genitourinary System Disease
  • Industry analysis
  • Drug Approval
  • Pharmaceutical Registrations

Endometriosis - Pipeline Review, H1 2020

  • $ 2000
  • April 2020
  • 148 pages

It was also under development for the treatment of colon carcinoma, teratocarcinoma, and lymphoma. [...] As of August 2013, it was in preclinical stage of development for the treatment of colon carcinoma, teratocarcinoma, and lymphoma. [...] When used as single agent, F8-IL4 inhibited tumor growth in three different immunocompetent murine cancer models (F9 teratocarcinoma, CT26 colon carcinoma and A20 lymphoma).

  • World
  • Pharmaceutical
  • Genitourinary System Disease
  • Industry analysis
  • Medical Technology Density
  • Pharmaceutical Registrations

Women Infertility - Pipeline Review, H1 2020

  • $ 2000
  • March 2020
  • 217 pages

It was also under development for the treatment of colon carcinoma, teratocarcinoma, and lymphoma. [...] As of August 2013, it was in preclinical stage of development for the treatment of colon carcinoma, teratocarcinoma, and lymphoma. [...] When used as single agent, F8-IL4 inhibited tumor growth in three different immunocompetent murine cancer models (F9 teratocarcinoma, CT26 colon carcinoma and A20 lymphoma).

  • World
  • Genitourinary System Disease
  • Industry analysis
  • Pregnancy Rate
  • Medical Technology Density

Endometriosis - Pipeline Review, H2 2019

  • $ 2000
  • November 2019
  • 134 pages

It was also under development for the treatment of colon carcinoma, teratocarcinoma, and lymphoma. [...] As of August 2013, it was in preclinical stage of development for the treatment of colon carcinoma, teratocarcinoma, and lymphoma. [...] When used as single agent, F8-IL4 inhibited tumor growth in three different immunocompetent murine cancer models (F9 teratocarcinoma, CT26 colon carcinoma and A20 lymphoma).

  • World
  • Pharmaceutical
  • Genitourinary System Disease
  • Industry analysis
  • Medical Technology Density
  • Pharmaceutical Registrations

Women Infertility - Pipeline Review, H2 2020

  • $ 2000
  • September 2020
  • 232 pages

It w as also under development f or the treatment of colon carcinoma, teratocarcinoma, and lymphoma. [...] As of August 2013, it w as in preclinical stage of development f or the treatment of colon carcinoma, teratocarcinoma, and lymphoma. [...] When used as single agent, F8-IL4 inhibited tumor grow th in three diff erent immunocompetent mur ine cancer models (F9 teratocarcinoma, CT26 colon carcinoma and A20 lymphoma).

  • World
  • China
  • Pharmaceutical
  • Genitourinary System Disease
  • Industry analysis
  • Birth Rate
  • Pregnancy Rate

Global Infertility Treatment Market 2018-2022

  • $ 2500
  • April 2018
  • 114 pages

• In January 2017, the company announced the FDA approval for IMBRUVICA (ibrutinib) as a first treatment specifically indicated for relapsed/refractory marginal zone lymphoma.

  • World
  • Healthcare
  • Genitourinary System Disease
  • Industry analysis
  • Fertility Rate
  • Online Retail Sales

Galectin 3 - Pipeline Review, H1 2020

  • $ 3500
  • February 2020
  • 81 pages

Scientists of MandalMed, Inc reported that they found activity of Galectin-3C in cells from solid tumors and lymphoma cell lines. [...] The expression of Galectin-3C in lymphoma cell lines that expressed galectin-## dramatically increased the sensitivity of the cells to induction of programmed cell death (apoptosis) by antibody to Fas.

  • World
  • Pharmaceutical
  • Therapy
  • Industry analysis
  • Health Provider Density
  • Dropout Rate

Galectin 3 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 82 pages

Scientists of MandalMed, Inc reported that they found activity of Galectin-3C in cells from solid tumors and lymphoma cell lines. [...] The expression of Galectin-3C in lymphoma cell lines that expressed galectin-## dramatically increased the sensitivity of the cells to induction of programmed cell death (apoptosis) by antibody to Fas.

  • World
  • Pharmaceutical
  • Therapy
  • Industry analysis
  • Health Provider Density
  • Dropout Rate

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2020

  • $ 2000
  • April 2020
  • 276 pages

The company's pipeline products include BR1006, BR1007, BR1008 for treating hypertension; BR2002, a drug used to treat lymphoma; and BR8003, a vaccine designed for the treatment of Hepatitis A. It also develops Kanarb, a drug used to treat hypertension; and Gelfos, an antacid for the treatment of hypergastric acidity, gastritis and gastric fullness.

  • World
  • United States
  • Chronic Disease
  • Genitourinary System Disease
  • Industry analysis
  • Drug Approval
  • Pharmaceutical Registrations

Chronic Kidney Disease - Pipeline Review, H1 2017

  • $ 2000
  • May 2017
  • 195 pages

Gazyva in combination with bendamustine followed by Gazyva monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen. [...] Gazyvaro (Obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyvaro maintenance in people with follicular lymphoma who did not respond or who progressed during or up to six months after treatment with MabThera (rituximab) or a MabThera-containing regimen. [...] Obinutuzumab (RG7159/GA101, afutuzumab) is under development for the treatment of non-Hodgkin lymphoma, diffuse large B-cell lymphoma, splenic marginal zone lymphoma, follicular lymphoma, Waldenstrom macroglobulinemia, B-cell follicular non-Hodgkin's lymphoma including indolent lymphoma, lupus nephritis and graft versus host disease.

  • World
  • Chronic Disease
  • Genitourinary System Disease
  • Industry analysis
  • Pharmaceutical Registrations
  • Drug Approval

Lupus Nephritis - Pipeline Review, H2 2016

  • $ 2000
  • September 2016
  • 142 pages

In June 2015, orphan designation (EU/##/##/##) was granted by the European Commission to Roche Registration Limited for obinutuzumab for the treatment of marginal zone lymphoma. [...] In June 2015, orphan designation (EU/##/##/##) was granted by the European Commission to Roche Registration Limited for obinutuzumab for the treatment of follicular lymphoma. [...] Roche announced that the European Commission has approved Gazyvaro (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyvaro maintenance in people with follicular lymphoma who did not respond after treatment with MabThera (rituximab).

  • World
  • South Africa
  • Pharmaceutical
  • Musculoskeletal Disorder
  • Industry analysis
  • Mortality Rate
  • Prescription Drug Sales

Renal Cluster Drug Development Pipeline Review, 2017

  • $ 3995
  • May 2017
  • 1 pages

The company's lead product, Pixuvri (pixantrone) is an aza-anthracenedione used for the treatment of multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) in adults.

  • World
  • Genitourinary System Disease
  • Chronic Disease
  • Industry analysis
  • Drug Approval
  • Prescription Drug Sales

Global Endometriosis Drugs Market 2016-2020

  • $ 2500
  • July 2016
  • 70 pages

Also, endometriosis is associated with infertility and many other complications such as heart attack, ovarian cancer, non- Hodgkin's lymphoma, and brain cancer.

  • World
  • APAC
  • Genitourinary System Disease
  • Therapy
  • Industry analysis
  • Drug Approval
  • Generics Use

Lupus Nephritis - Pipeline Review, H1 2016

  • $ 2000
  • April 2016
  • 135 pages

Obinutuzumab is indicated in combination with idasanutlin for the treatment of relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma. [...] Gazyva in combination with bendamustine followed by Gazyva monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab - containing regimen. [...] Obinutuzumab (RG7159/GA101, afutuzumab) is under development for the treatment of non-Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, B-cell follicular non-Hodgkin's lymphoma including indolent lymphoma and lupus nephritis.

  • World
  • Pharmaceutical
  • Musculoskeletal Disorder
  • Industry analysis
  • Mortality Rate
  • Prescription Drug Sales

OpportunityAnalyzer: Endometriosis - Opportunity Analysis and Forecast to 2025

  • $ 10995
  • November 2016
  • 288 pages

The etiology of endometriosis remains poorly understood despite decades of research (Ahn et al., [...] The etiology of endometriosis is complex and multifactorial, involving a combination of hormonal, genetic, immune, and environmental components (Sourial et al., [...] There are clear molecular distinctions between endometriosis lesions and normal endometrium, including overproduction of estrogen, prostaglandins, and cytokines in endometriotic tissues (Bulun, 2009).

  • United States
  • Japan
  • Genitourinary System Disease
  • Industry analysis
  • Drug Approval
  • Fertility Rate


View report >

Tecentriq Investor presentation

  • July 2019
  • 73 pages

• MabThera (onc) EU (-33%): Erosion rate slows • Gazyva (+38%): Growth driven by 1L FL [...] • US: Market entry of Rituxan biosimilars expected in November • EU: Polivy approval in R/R DLBCL [...] CER=Constant Exchange Rates; FL=follicular lymphoma; CLL=chronic lymphoid leukemia; AML=acute myeloid leukemia; DLBCL=diffuse large B-cell lymphoma; * Venclexta sales are booked by AbbVie.

  • United States
  • World
  • Lymphoma
  • Immunology
  • Investor presentation
  • Company
  • Prescription Drug Sales
  • Health Insurance Claims

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on